WLF Answers Democrats In First Amendment Off-Label Promotion Debate
This article was originally published in The Gray Sheet
Executive Summary
Off-label information is not "inherently misleading," and consequently FDA should ease restrictions for disseminating it, the Washington Legal Foundation asserts in its response to congressional Democrats' interpretation of First Amendment case law
You may also be interested in...
CDRH More Reliant On SEC, FTC For Ad/Promotion Vigilance Under Policy Shift
The Center for Devices & Radiological Health increasingly is looking to other federal agencies to help regulate medical device advertising and promotion as it scales back its own claim enforcement activities
CDRH More Reliant On SEC, FTC For Ad/Promotion Vigilance Under Policy Shift
The Center for Devices & Radiological Health increasingly is looking to other federal agencies to help regulate medical device advertising and promotion as it scales back its own claim enforcement activities
FDA Pre-Approval Of Commercial Speech: “Coming Soon” To DTC Device Ads?
AdvaMed is urging FDA to consider a pre-approval policy for direct-to-consumer advertising within the Center for Devices & Radiological Health